SRF617 not checked

Coherus Oncology, Inc.

FollowEvery change as it happens, and a Monday email
Stage
No active trials
 
Next date
None yet
 
Trials
0 active
2 in total
Targets
—
None known yet

What this is

How it works
How it works isn't classified yet
How it’s given
“SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39.”In the company’s words, NCT05177770 on ClinicalTrials.gov
Tested for
Metastatic Castration-resistant Prostate Cancer, Prostate Cancer, Advanced Solid Tumor
Main trialPhase 2
“This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).”In the company’s words, NCT05177770 on ClinicalTrials.gov

Other drugs for Metastatic Castration-resistant Prostate Cancer

All 194 drugs for Metastatic Castration-resistant Prostate Cancer

Coming up0

No dates coming up.

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials2

TrialPhaseCompletesWhat it tests
Phase 2Terminated 5 Apr 2023 Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer
Phase 1Completed 25 Aug 2023 Study of SRF617 in Patients With Advanced Solid Tumors
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow SRF617

Following is part of Solo: you see every change to SRF617 the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in